Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iclepertin with Computerized Cognitive Training in Schizophrenia
NCT03859973Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2019
- Primary completion
- Sep 2022
- Modality
- Classical Binding Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing Iclepertin + CCT with Placebo + CCT (2 arms). Primary endpoint: Change From Baseline in Neurocognitive Function as Measured by the Neurocognitive Composite Score of the MATRICS Consensus Cognitive Battery (MCCB) at 12 weeks. Started Apr 2019; status: completed.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03859973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03859973.